PMID- 15785379
OWN - NLM
STAT- MEDLINE
DCOM- 20050425
LR  - 20221207
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 79
IP  - 6
DP  - 2005 Mar 27
TI  - Induction therapy with basiliximab versus Thymoglobulin in African-American 
      kidney transplant recipients.
PG  - 716-21
AB  - BACKGROUND: It has been suggested that the use of antilymphocyte induction 
      therapy in African-American (AA) renal transplant recipients reduces the risk of 
      acute rejection (AR) and improves graft survival. It is not clear whether the 
      efficacy of basiliximab (BSX) is different from that of Thymoglobulin (ATG) in 
      this regard. METHODS: We retrospectively assessed the effect of induction therapy 
      with BSX versus ATG in 88 AA renal allograft recipients receiving transplants at 
      our center between July 2001 and June 2003 and followed for 19+/-7 months. All 
      patients were maintained on mycophenolate mofetil, prednisone, and either 
      tacrolimus or sirolimus. Study endpoints included patient and graft survival, 
      graft function, and incidence of AR and cytomegalovirus infection. Regression 
      models were used to evaluate the independent effect of each induction agent on 
      these endpoints. RESULTS: Thirty-six patients received ATG, and 52 received BSX. 
      The groups were comparable with regard to donor race and age, and recipient sex, 
      body mass index, human leukocyte antigen (HLA) matching, and hepatitis C virus 
      serostatus. The ATG group was younger, more likely to receive retransplant, had 
      longer duration of end-stage renal disease and higher panel reactive antibody, 
      and was less likely to receive live-donor organs. However, after adjusting for 
      all these variables, graft outcomes, as well as renal function, were comparable 
      between the two induction groups. We found that the degree of HLA mismatch, 
      delayed graft function, and AR were the only significant predictors of graft 
      loss. CONCLUSION: The results of our study suggest that the choice of induction 
      agent may not have a major impact on graft outcomes in AA renal-allograft 
      recipients.
FAU - Haririan, Abdolreza
AU  - Haririan A
AD  - Division of Nephrology, Department of Medicine, Wayne State University School of 
      Medicine, Detroit, MI, USA. aharirian@med.wayne.edu
FAU - Morawski, Katherina
AU  - Morawski K
FAU - Sillix, Dale H
AU  - Sillix DH
FAU - El-Amm, Jose M
AU  - El-Amm JM
FAU - Garnick, James
AU  - Garnick J
FAU - West, Miguel S
AU  - West MS
FAU - Granger, Darla K
AU  - Granger DK
FAU - Migdal, Stephen D
AU  - Migdal SD
FAU - Gruber, Scott A
AU  - Gruber SA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9927MT646M (Basiliximab)
RN  - MU72812GK0 (Creatine)
SB  - IM
MH  - Adult
MH  - *Black or African American
MH  - Antibodies, Monoclonal/*immunology/therapeutic use
MH  - Antilymphocyte Serum/*immunology/therapeutic use
MH  - Basiliximab
MH  - Creatine/blood
MH  - Female
MH  - Graft Survival/drug effects/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Kidney Transplantation/*immunology
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Proportional Hazards Models
MH  - Recombinant Fusion Proteins/*immunology/therapeutic use
MH  - Retrospective Studies
MH  - Transplantation
MH  - Transplantation, Homologous/immunology
EDAT- 2005/03/24 09:00
MHDA- 2005/04/26 09:00
CRDT- 2005/03/24 09:00
PHST- 2005/03/24 09:00 [pubmed]
PHST- 2005/04/26 09:00 [medline]
PHST- 2005/03/24 09:00 [entrez]
AID - 00007890-200503270-00018 [pii]
AID - 10.1097/01.tp.0000153506.07816.f0 [doi]
PST - ppublish
SO  - Transplantation. 2005 Mar 27;79(6):716-21. doi: 
      10.1097/01.tp.0000153506.07816.f0.